Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous infusion solutions for drug delivery in home and ambulatory care settings. Its Freedom Syringe Infusion System includes Freedom60 and FreedomEDGE syringe infusion drivers, Precision Flow Rate Tubing, and HigH-Flo Subcutaneous Safety Needle Sets.
Company updates commonly cover quarterly results, revenue guidance, cash flow trends, FDA 510(k) clearances, EU MDR certification, and label expansions, including FreedomEDGE use for RYSTIGGO delivery. News also addresses pharma services and clinical-trial collaborations with biopharmaceutical companies, customization of the Freedom System across drug categories, and governance or leadership succession matters.
KORU Medical (NASDAQ: KRMD) presented real-world data on its FreedomEDGE syringe infusion system at the 51st Annual Oncology Nursing Society Congress.
The multi-site study across four U.S. community infusion centers reported 100% successful dosing, reduced nurse strain, high nurse (4.85/5) and patient (4.92/5) satisfaction, and workflow benefits.
KORU’s FREEDOM system supports 5–50mL+ subcutaneous infusions and is used by 59,000+ patients for over 3M infusions annually, with a 97% adherence rate, 9 on-label drugs, and approval in 30+ countries.
KORU Medical (NASDAQ: KRMD) reported Q1 2026 net revenues of $11.8M, up 22.1% year‑over‑year, with gross profit of $7.2M and gross margin of 61.5%.
Net loss narrowed to ($0.8M) and cash totaled $8.8M as of March 31, 2026. The company reiterated full‑year 2026 revenue guidance of $47.5M–$50.0M and gross margin guidance of 61%–63%.
KORU Medical (NASDAQ: KRMD) will report first quarter 2026 financial results on Wednesday, May 6, 2026. Management will host a conference call and live webcast at 4:30 p.m. ET to discuss results and provide a corporate update.
Call dial-ins: (877) 407-0784 (U.S./Canada) and (201) 689-8560 (international). A live and archived webcast will be available via the investor relations calendar at www.korumedical.com; the archive will remain available for six months.
KORU Medical Systems (NASDAQ: KRMD) announced EU MDR certification for its Freedom60® Infusion Pump, including the 50 mL prefilled syringe adapter, enabling commercialization across the European Union. Freedom60 complements the FreedomEDGE® system (20 mL syringe compatibility) to expand prefilled syringe options for subcutaneous immunoglobulin (SCIg) therapy.
The certification aims to simplify home infusion, reduce preparation and handling steps, and broaden patient access to intuitive large-volume subcutaneous delivery across Europe.
KORU Medical (NASDAQ: KRMD) announced a planned CEO transition: Linda Tharby will retire effective June 30, 2026, and Adam Kalbermatten, currently Chief Commercial Officer, will assume the CEO role effective July 1, 2026 (appointed President effective March 15, 2026).
Under Tharby, the company doubled its recurring patient base to over 55,000, expanded internationally, broadened the Freedom infusion platform beyond immunoglobulin, delivered consistent revenue growth, and achieved profitability. Tharby will remain on the board and advise through the end of 2026.
KORU Medical (NASDAQ: KRMD) reported strong 2025 results with full-year net revenues of $41.1M (up 22%) and fourth-quarter revenues of $10.9M (up 23%). Gross profit rose to $25.6M with 62.3% margin. Net loss improved to $2.6M and adjusted EBITDA turned positive at $0.6M. Ending cash was $8.9M. The company received a 510(k) clearance, announced EU MDR certification, expanded pharma collaborations, and initiated 2026 guidance of $47.5–$50.0M revenue with positive adjusted EBITDA and cash flow.
KORU Medical Systems (NASDAQ: KRMD) will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026.
Management will host a conference call and live webcast at 4:30 p.m. ET. Dial-in numbers and a live/archived webcast are available via the company's investor relations calendar at www.korumedical.com. The archived webcast will be available for six months.
KORU Medical (NASDAQ: KRMD) received FDA 510(k) clearance to use the FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), expanding the FreedomEDGE label to include administration by a healthcare professional and broadening access for patients with generalized myasthenia gravis (gMG).
The clearance covers weekly 3–6 mL subcutaneous infusions over 15–30 minutes for six weeks with subsequent cycles per clinical evaluation. Freedom System metrics: 15+ years home use history, 45,000+ patients, 2M+ infusions annually, 97% adherence, and 9 on-label subcutaneous drugs across 30+ countries.
KORU Medical (NASDAQ: KRMD) reported preliminary unaudited results for Q4 and full year ended December 31, 2025. Preliminary Q4 net revenues are expected to be $10.9 million (+23% YoY) and preliminary full-year net revenues are expected to be $41.1 million (+22% YoY). The company reported an ending cash balance of $8.9 million and stated it achieved positive cash flow in Q4 and positive operating cash flow for the full year 2025. Management highlighted continued strength in the immunoglobulin business, growth in the recurring patient base, ongoing international expansion, and a recent 510(k) submission for the Freedom Infusion System for use with Phesgo® intended to expand into oncology. Final audited results and 2026 guidance are planned for early March 2026.
KORU Medical (NASDAQ: KRMD) awarded inducement equity to its new Chief Technology Officer under his employment agreement dated December 11, 2025. On January 2, 2026, the company granted nonqualified stock options to purchase 232,297 shares at an exercise price of $5.70 and 76,426 restricted shares.
Each award vests 25% on each anniversary of the grant date, subject to the award agreements and possible accelerated vesting. The Compensation Committee approved the awards as an inducement material to employment under Nasdaq Listing Rule 5635(c)(4).